ClinicalTrials.gg
RecruitingNCT06931691PNH-NISUpdated Jun 1, 2026

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

An observational study in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals. Recruiting at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.

Started
2025
with 3 others
Observational
7 of 16
4 open now
Registered
11th of 16
by date

Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is one of 4 that started in 2025, is one of 7 observational ones, and was the 11th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hemoglobinuria, Paroxysmal by Novartis, or all of them as a file.
02

Study summary

The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients.

Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Phase IV
  • Adult Patients
  • Paroxysmal Nocturnal Hemoglobinuria
  • LNP023
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult PNH patients receiving iptacopan for the first time, including those who are complement inhibitor naive and treated

Eligibility criteria

Inclusion criteria For Cohort 1,

Patient who meets all the following criteria can be included in this study:

  1. Age ≥ 18 years at the time of signing the ICF;
  2. Patient with a documented diagnosis of PNH;
  3. Patient who has never received complement inhibitor therapy;
  4. Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF;
  5. Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation; If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible.
  6. Patient who has signed the ICF.

For Cohort 2,

Patient who meets all the following criteria can be included in this study:

  1. Age ≥ 18 years at the time of signing the ICF;
  2. Patient with a documented diagnosis of PNH; Patients who have been receiving stable treatment with C5 complement inhibitors for at least three months prior to enrollment;
  3. Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF;
  4. Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation;
  5. If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible.
  6. Patient who has signed the ICF. Exclusion criteria

For Cohort 1 and Cohort 2, patients who meet any of the following criteria will meet the exclusion criteria for this study:

  1. Participating in an interventional PNH clinical study;
  2. Have an active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to first dose;
  3. Documented with a history of recurrent invasive infections, e.g. active systemic bacterial, viral or fungal infection within 14 days prior to first dose;
  4. Documented with a history of infection;
  5. Women who are pregnant or breastfeeding or intending to conceive during the study period;
  6. Existence of bone marrow failure (reticulocytes \< 100 × 109/L, \< 30 × 109/L, and neutrophils \< 0.5 × 109/L) determined by the investigator;
  7. Other conditions that are not suitable for participating in the study, in the judgment of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort1

    PNH patients with a confirmed diagnosis of PNH in the medical record and who had never received complement inhibitor therapy (complement inhibitor naive patients)

    Drug: LNP023

  • Cohort 2

    PNH patients with a confirmed diagnosis of PNH in the medical record who had been treated with a stable dose of a C5 complement inhibitor (e.g., eculizumab) for at least 3 months (C5i-treated patients; this cohort will be only start enrollment after the indication for iptacopan is to be approved in China).

    Drug: LNP023

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in hemoglobin (Hb) levels at designated time points

    Assessment of the Hematological Response to iptacopan.

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Number of participants having Hb normalization (Hb level ≥ 12 g/dL) after iptacopan initiation.

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  2. Duration of Hb level ≥ 12 g/dL within a 12-month

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  3. Change from baseline in LDH Levels after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 Months

  4. Number of participants with LDH levels ≤ 1.5 x ULN before vs. after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  5. Number of participants having LDH normalization before and after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 monhts

  6. Duration of LDH level ≤ 1.5 x ULN within 12 months

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  7. Change from baseline in ARC Levels after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 monhts

  8. Number of participants having ARC normalization before and after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 months

  9. Change from baseline in bilirubin after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 months

  10. Number of participants with hepatosplenomegaly before and after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 months

  11. Number of participants with a positive coomb's test after iptacopan initiation

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  12. Number of participants with PNH related signs or symptoms before and after iptacopan treatment

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: Baseline, 12 months

  13. Change from baseline in PNH clone value

    Change from baseline in flow cytometry results to assess the impact of iptacopan on Treatment-Related Outcomes.

    Time frame: Baseline, 12 months

  14. Rate, reasons (complement activation conditions (CAC), missed doses, etc.), duration, and interventions for breakthrough hemolysis (BTH)

    Assessing the Impact of iptacopan on Treatment-Related Outcomes

    Time frame: 12 months

  15. Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale after iptacopan initiation

    FACIT is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function to assess the Impact of iptacopan on Treatment-Related Outcomes. The minimum value is 0 and maximum value is 52, and higher scores mean a worse outcome.

    Time frame: Baseline, 12 months

  16. Work Productivity and Activity Impairment Questionnaire-Specific Health Problems (WPAI-SHP) at each visit, change from baseline in WPAI-SHP after iptacopan initiation

    WPAI-SHP is a tool used to measure the impact of health problems on work productivity and regular activities. The scale includes several components. Absenteeism: This measures the percentage of work time missed due to a specific health problem. Presenteeism: This measures the percentage of impairment while working due to the health problem. Work productivity loss: This combines absenteeism and presenteeism to measure overall work impairment. Activity impairment: This measures the percentage of impairment in regular activities due to the health problem. The scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, which means worse outcomes.

    Time frame: Baseline, 12 months

  17. Adverse events (AEs) and Serious adverse events (SAEs) occurring during treatment with iptacopan

    Assessing the safety of iptacopan

    Time frame: 12 monhts

  18. Treatment regimen for PNH 12 months before iptacopan treatment; reasons of discontinuation of previous complement inhibitor;

    Assessing the impact of iptacopan on disease management

    Time frame: Baseline

  19. Use of concomitant medications (e.g., corticosteroids, androgen, immunosuppressants, anti-coagulants, etc.) for PNH and PNH-related complications (e.g. thrombosis, renal failure, etc.) before and after iptacopan treatment;

    Assessing the impact of iptacopan on disease management

    Time frame: Baseline, 12 months

  20. Duration of iptacopan treatment, reasons for discontinuation, switching to other treatments, proportion of patients who switch from iptacopan to other treatments;

    Assessing the impact of iptacopan on disease management

    Time frame: 12 monhts

  21. Number of participants with blood transfusion before and after iptacopan treatment, duration and number of units of blood transfusion due to BTH

    Assessing the impact of iptacopan on disease management

    Time frame: Baseline, 12 months

  22. Number of participants hospitalized, outpatient, emergency room and intensive care unit (ICU) visits related to PNH

    Assessing the impact of iptacopan on healthcare resource utilization

    Time frame: 12 monhts

  23. Length of inpatient stay related to PNH

    Assessing the impact of iptacopan on healthcare resource utilization

    Time frame: 12 months

07

Study locations

14 of 14 sites recruiting
  • Novartis Investigative Site
    Hefei, Anhui 230022, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
    Recruiting
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
    Recruiting
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
    Recruiting
  • Novartis Investigative Site
    Zhengzhou, Henan 450008, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
    Recruiting
  • Novartis Investigative Site
    Nantong, Jiangsu 226000, China
    Recruiting
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
    Recruiting
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
    Recruiting
  • Novartis Investigative Site
    Jinan, 250012, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300020, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300052, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, 430022, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Apr 17, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Apr 21, 2027
CompletionEst.
Apr 21, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06931691
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Jun 10, 2025
Primary completion
Apr 21, 2027 (estimated)
Completion
Apr 21, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion